On September 19, 2024, Gregory Bailey, Director at Serina Therapeutics Inc (SER, Financial), purchased 14,388 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 62,240 shares of Serina Therapeutics Inc.
Serina Therapeutics Inc specializes in the development of polymer-based drugs designed to enhance the effectiveness and safety of therapeutic molecules. The company's innovative approach focuses on improving drug delivery mechanisms which can lead to better patient outcomes.
Over the past year, the insider has increased their holdings by purchasing a total of 61,970 shares. There have been 13 insider buys and no insider sells at Serina Therapeutics Inc over the same period, indicating a positive trend in insider confidence.
Shares of Serina Therapeutics Inc were priced at $6.13 on the day of the transaction. The company has a market cap of approximately $58.795 million. The price-earnings ratio of the stock stands at 20.07, which is below the industry median of 24.245.
For more detailed valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow, interested investors may refer to the GF Value of the stock.
This insider purchase could signal a bullish outlook from the director, aligning with the overall insider buying trend at the company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
